• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于 SARS-CoV-2 病毒相关性心动过缓作为死亡率预测因子的新研究——回顾性多中心分析。

A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis.

机构信息

Department of Internal Medicine, Hemet Global Medical Center, Hemet, California, USA.

Divison of Cardiology, Loma Linda University School of Medicine, Loma Linda, California, USA.

出版信息

Clin Cardiol. 2021 Jun;44(6):857-862. doi: 10.1002/clc.23622. Epub 2021 May 8.

DOI:10.1002/clc.23622
PMID:33964035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8207973/
Abstract

BACKGROUND

SARS-CoV2 has affected more than 73.8 million individuals. While SARS-CoV2 is considered a predominantly respiratory virus, we report a trend of bradycardia among hospitalized patients, particularly in association with mortality.

METHODOLOGY

The multi-center retrospective analysis consisted of 1053 COVID-19 positive patients from March to August 2020. A trend of bradycardia was noted in the study population. Absolute bradycardia and profound bradycardia was defined as a sustained heart rate < 60 BPM and < 50 BPM, respectively, on two separate occasions, a minimum of 4 h apart during hospitalization. Each bradycardic event was confirmed by two physicians and exclusion criteria included: less than 18 years old, end of life bradycardia, left AMA, or taking AV Nodal blockers. Data was fetched using a SQL program through the EMR and data was analyzed using SPSS 27.0. A logistic regression was done to study the effect of bradycardia, age, gender, and BMI on mortality in the study group.

RESULTS

24.9% patients had absolute bradycardia while 13.0% had profound bradycardia. Patients with absolute bradycardia had an odds ratio of 6.59 (95% CI [2.83-15.36]) for mortality compared with individuals with a normal HR response. The logistic regression model explained 19.6% (Nagelkerke R ) of variance in the mortality, correctly classified 88.6% of cases, and was statistically significant X (5)=47.10, p < .001. For each year of age > 18, the odds of dying increased 1.048 times (95% CI [1.25-5.27]).

CONCLUSION

The incidence of absolute bradycardia was found in 24.9% of the study cohort and these individuals were found to have a significant increase in mortality.

摘要

背景

SARS-CoV2 已影响超过 7380 万人。虽然 SARS-CoV2 被认为主要是一种呼吸道病毒,但我们报告了住院患者心动过缓的趋势,特别是与死亡率相关的趋势。

方法

这项多中心回顾性分析纳入了 2020 年 3 月至 8 月期间的 1053 名 COVID-19 阳性患者。研究人群中注意到心动过缓的趋势。绝对心动过缓及严重心动过缓定义为两次间隔至少 4 小时,在住院期间两次分别至少持续 4 小时,心率 < 60 BPM 和 < 50 BPM。每次心动过缓事件均由两名医生确认,并排除标准包括:年龄小于 18 岁、生命终末期心动过缓、左前降支病变或服用房室结阻滞剂。使用 EMR 中的 SQL 程序获取数据,并使用 SPSS 27.0 进行数据分析。使用逻辑回归研究研究组中心动过缓、年龄、性别和 BMI 对死亡率的影响。

结果

24.9%的患者存在绝对心动过缓,13.0%的患者存在严重心动过缓。与正常 HR 反应者相比,存在绝对心动过缓的患者的死亡比值比为 6.59(95%CI[2.83-15.36])。逻辑回归模型解释了死亡率的 19.6%(Nagelkerke R)的变异性,正确分类了 88.6%的病例,且统计学上显著(X(5)=47.10,p<.001)。年龄每增加 1 岁,死亡的几率增加 1.048 倍(95%CI[1.25-5.27])。

结论

研究队列中发现 24.9%的患者存在绝对心动过缓,这些患者的死亡率显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b52/8207973/0087d95e0260/CLC-44-857-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b52/8207973/0087d95e0260/CLC-44-857-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b52/8207973/0087d95e0260/CLC-44-857-g001.jpg

相似文献

1
A novel study on SARS-COV-2 virus associated bradycardia as a predictor of mortality-retrospective multicenter analysis.一项关于 SARS-CoV-2 病毒相关性心动过缓作为死亡率预测因子的新研究——回顾性多中心分析。
Clin Cardiol. 2021 Jun;44(6):857-862. doi: 10.1002/clc.23622. Epub 2021 May 8.
2
A Multicenter Retrospective Analysis on the Etiology of Bradycardia in COVID-19 Patients.新型冠状病毒肺炎患者心动过缓病因的多中心回顾性分析
Cureus. 2022 Jan 16;14(1):e21294. doi: 10.7759/cureus.21294. eCollection 2022 Jan.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study.与挪威所有确诊 COVID-19 病例住院、有创机械通气治疗和死亡相关的因素:前瞻性队列研究。
Scand J Public Health. 2021 Feb;49(1):41-47. doi: 10.1177/1403494820985172. Epub 2021 Jan 18.
5
Comparison of hospitalized patients with COVID-19 who did and did not live in residential care facilities in Montréal: a retrospective case series.比较在蒙特利尔居住在和未居住在长期护理院的 COVID-19 住院患者:一项回顾性病例系列研究。
CMAJ Open. 2021 Jul 13;9(3):E718-E727. doi: 10.9778/cmajo.20200244. Print 2021 Jul-Sep.
6
Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism.瑞德西韦在住院治疗 SARS-CoV2 感染患者中引起的心动过缓:一种可能的迷走神经介导机制。
Intern Emerg Med. 2023 Mar;18(2):359-366. doi: 10.1007/s11739-022-03168-6. Epub 2022 Dec 21.
7
Outcomes of hospital-acquired SARS-CoV-2 infection in the Canadian first wave epicentre: a retrospective cohort study.加拿大第一波疫情中心医院获得性 SARS-CoV-2 感染的结局:一项回顾性队列研究。
CMAJ Open. 2022 Feb 1;10(1):E74-E81. doi: 10.9778/cmajo.20210055. Print 2022 Jan-Mar.
8
Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.在加拿大,167500 例 COVID-19 患者中,先前存在的合并症与死亡率和疾病严重程度的关系:一项基于人群的队列研究。
PLoS One. 2021 Oct 5;16(10):e0258154. doi: 10.1371/journal.pone.0258154. eCollection 2021.
9
Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.ACEi 和 ARB 在 COVID-19 管理中的安全性:回顾性分析。
Clin Cardiol. 2022 Jul;45(7):759-766. doi: 10.1002/clc.23836. Epub 2022 Apr 28.
10
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.一项评估巴瑞替尼预防 COVID19 相关血液肿瘤患者呼吸功能不全进展的疗效的 I/II 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Feb 5;22(1):116. doi: 10.1186/s13063-021-05072-4.

引用本文的文献

1
Sleep and cardiorespiratory function assessed by a smart bed over 10 weeks post COVID-19 infection.新冠病毒感染后10周内,通过智能床评估睡眠和心肺功能。
Sci Rep. 2025 Jan 21;15(1):2724. doi: 10.1038/s41598-025-87069-6.
2
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.使用瑞德西韦治疗2019冠状病毒病时心动过缓的发生率及危险因素分析。
Int J Crit Illn Inj Sci. 2024 Oct-Dec;14(4):203-207. doi: 10.4103/ijciis.ijciis_57_24. Epub 2024 Dec 23.
3
Pathophysiological correlations between SARS-CoV-2 and arrhythmogenesis: a literature review.

本文引用的文献

1
Acute Cardiac Injury in COVID-19: A Systematic Review and Meta-analysis.新型冠状病毒肺炎相关的急性心脏损伤:系统评价和荟萃分析。
Arch Iran Med. 2020 Nov 1;23(11):801-812. doi: 10.34172/aim.2020.107.
2
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关的显著窦性心动过缓:1例病例及文献综述
JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.
3
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.
新型冠状病毒(SARS-CoV-2)与心律失常发生之间的病理生理相关性:文献综述
Germs. 2024 Mar 31;14(1):63-76. doi: 10.18683/germs.2024.1418. eCollection 2024 Mar.
4
Exploring the impact of electrocardiographic parameters on the risk of common arrhythmias: a two-sample Mendelian randomization study.探索心电图参数对常见心律失常风险的影响:一项两样本孟德尔随机化研究。
J Thorac Dis. 2024 Jul 30;16(7):4553-4566. doi: 10.21037/jtd-24-814. Epub 2024 Jul 26.
5
Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.瑞德西韦在新冠病毒感染中导致的心动过缓和死亡率:潜在风险因素评估——一项系统评价与荟萃分析
J Clin Med. 2023 Dec 5;12(24):7518. doi: 10.3390/jcm12247518.
6
COVID-19-Induced Complete Heart Block: Case Series and Literature Review.新冠病毒感染所致完全性心脏传导阻滞:病例系列与文献综述
Cureus. 2023 Apr 13;15(4):e37517. doi: 10.7759/cureus.37517. eCollection 2023 Apr.
7
Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study.瑞德西韦与新型冠状病毒肺炎患者窦性心动过缓的相关性:一项前瞻性纵向研究。
Front Pharmacol. 2023 Jan 17;13:1107198. doi: 10.3389/fphar.2022.1107198. eCollection 2022.
8
Unmasking the 'Asymptomatic' COVID-19: A Nose Question.揭开“无症状”新冠病毒感染的面纱:一个关于鼻子的问题。
Life (Basel). 2022 Aug 16;12(8):1248. doi: 10.3390/life12081248.
9
Remdesivir-induced Bradycardia is not Associated with Worse Outcome in Patients with COVID-19: A Retrospective Analysis.瑞德西韦引起的心动过缓与 COVID-19 患者的不良结局无关:一项回顾性分析。
Am J Cardiovasc Drugs. 2022 Nov;22(6):705-710. doi: 10.1007/s40256-022-00547-4. Epub 2022 Aug 25.
10
Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.瑞德西韦治疗的 COVID-19 患者心动过缓的临床特征及意义:一项单中心回顾性队列研究。
Clin Drug Investig. 2022 Sep;42(9):763-774. doi: 10.1007/s40261-022-01187-x. Epub 2022 Aug 17.
血管紧张素转换酶2(ACE2):严重急性呼吸综合征冠状病毒2(SARS-CoV-2)受体和肾素-血管紧张素系统(RAS)调节剂
Acta Pharm Sin B. 2021 Jan;11(1):1-12. doi: 10.1016/j.apsb.2020.10.006. Epub 2020 Oct 13.
4
Relative bradycardia as a clinical feature in patients with coronavirus disease 2019 (COVID-19): A report of two cases.相对心动过缓作为2019冠状病毒病(COVID-19)患者的临床特征:两例报告
J Cardiol Cases. 2020 Dec;22(6):260-264. doi: 10.1016/j.jccase.2020.07.015. Epub 2020 Jul 25.
5
Relative bradycardia in patients with COVID-19.新型冠状病毒肺炎患者的相对心动过缓
Clin Microbiol Infect. 2021 Feb;27(2):295-296. doi: 10.1016/j.cmi.2020.08.013. Epub 2020 Aug 18.
6
COVID-19 and cardiac arrhythmias.新型冠状病毒肺炎与心律失常。
Heart Rhythm. 2020 Sep;17(9):1439-1444. doi: 10.1016/j.hrthm.2020.06.016. Epub 2020 Jun 22.
7
Bradycardia in Patients With COVID-19: A Calm Before the Storm?新型冠状病毒肺炎患者的心动过缓:暴风雨前的平静?
Cureus. 2020 Jun 13;12(6):e8599. doi: 10.7759/cureus.8599.
8
COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.新型冠状病毒肺炎与心律失常:心律失常特征及管理策略的全球视角
J Interv Card Electrophysiol. 2020 Nov;59(2):329-336. doi: 10.1007/s10840-020-00789-9. Epub 2020 Jun 3.
9
[ANMCO Position paper: Guidance for the management of suspected or confirmed COVID-19 patients requiring urgent electrophysiological procedures].[意大利心脏病学国家协会立场文件:对疑似或确诊的 COVID-19 患者进行紧急电生理手术管理的指南]
G Ital Cardiol (Rome). 2020 May;21(5):336-340. doi: 10.1714/3343.33130.
10
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).新冠肺炎(COVID-19)患者的心脏受累。
JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096.